Emergency Department Management of Acute Venous Thromboembolism in Patients With Obesity With Intravenous Unfractionated Heparin and Anti-Xa Monitoring
Restricted accessResearch articleFirst published online June, 2023
Emergency Department Management of Acute Venous Thromboembolism in Patients With Obesity With Intravenous Unfractionated Heparin and Anti-Xa Monitoring
Background: Unfractionated heparin (UFH) remains a frequently utilized agent in the emergency department (ED) for management of acute venous thromboembolism (VTE). While various protocols of UFH dosing have been proposed for patients with obesity, the optimal dosing and monitoring strategy is unclear. Objective: This study aims to compare the time to the first therapeutic anti-Xa level in obese acute VTE patients following the use of either total body weight (TBW) or adjusted body weight-based (AdjBW) dosing of UFH in the ED, and to analyze the impact of different dosing strategies on patient outcomes. Methods: Inclusion criteria included adult patients with a BMI > 30 kg/m2, and suspected VTE managed with UFH per institutional protocol utilizing a bolus dose followed by maintenance infusion and anti-Xa monitoring. The primary outcome was time to the first therapeutic anti-Xa level in the group dosed per TBW compared with the group dosed per AdjBW. Safety outcomes included incidence of bleeding events, protamine administration, and mortality. Results: There were 32 patients included in the study. Patients dosed per TBW achieved a median time to first therapeutic anti-Xa level of 14.5 hours compared with 15 hours in the AdjBW group (P = .613). The median therapeutic UFH infusion rate was 16 units/kg/hr in the TBW group compared with 13.5 units/kg/hr in the AdjBW group (P < .001). Safety outcomes were not significantly different between groups. Conclusion: Patients presenting to the ED with acute VTE may be managed with UFH using either a TBW or AdjBW dosing strategy.
HullRDRaskobGERosenbloomD, et al.Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992;152(8):1589-1595.
2.
HullRDRaskobGEBrantRF, et al.Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med. 1997;157(22):2562-2568.
3.
SingerAJThodeHCPeacockWF. Admission rates for emergency department patients with thromboembolism and estimation of the proportion of low risk pulmonary of low-risk pulmonary embolism patients: a US perspective. Clin Exp Emerg Med. 2016;3(3):126-131.
4.
GarciaDABaglinTPWeitzJI, et al.Parenteral anticoagulants. Antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e24S-e43S.
5.
KearonCAklEAComerotaAJ, et al.Antithrombotic therapy for VTE disease. Antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S-e494S.
6.
KearonCAklEAOrnelasJ, et al.Antithrombotic therapy for VTE disease. CHEST guideline and expert panel report. Chest. 2016;149(2):315-352.
7.
SmytheMAPriziolaJDobeshP, et al.Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):165-186.
8.
SchaeferDCHufnagleJWilliamsL. Rapid heparin anticoagulation: use of a weight-based nomogram. Am Fam Physician. 1996;54(8):2517-2521.
9.
MyzienskiAELutzMFSmytheMA. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: Case report and review of the literature. Pharmacotherapy. 2010;30(3):105e-112e.
10.
CukerA. Unfractionated heparin for the treatment of venous thromboembolism: Best practices and areas of uncertainty. Semin Thromb Hemost. 2012;38(6):593-599.
11.
HurewitzANKhanSUGrothML, et al.Dosing of unfractionated heparin in obese patients with venous thromboembolism. J Gen Intern Med. 2011;26(5):487-491.
12.
AnandSGinsbergJSKearonC, et al.The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med. 1996;156(15):1677-1681.
13.
AnandSSBatesSGinsbergJS, et al.Recurrent venous thrombosis and heparin therapy: An evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med. 1999;159(17):2029-2032.
14.
EichingerSHronGBialonczykC, et al.Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008;168(15):1678-1683.
15.
GuervilDJWintersteinAGJohnsTW, et al.Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother. 2011;45:861-868.
16.
EbiedAMLiTAxelrodSF, et al.Intravenous unfractionated heparin dosing in obese patients using anti-XA levels. J Thromb Thrombolysis. 2020;49(2):206-213.
17.
SchulmanSKearonC. Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis.The definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
18.
HoschLMBreedloveEYSconoLE, et al.Evaluation of an unfractionated heparin pharmacy dosing protocol for the treatment of venous thromboembolism in nonobese, obese, and severely obese patients. Ann Pharmacother. 2017;51(9):768-773.
19.
IsherwoodMMurphyMLBinghamAL, et al.Evaluation of safety and effectiveness of standardized antifactor Xa-based unfractionated heparin protocols in obese versus non-obese patients. J Thromb Thrombolysis. 2017;43(4):476-483.
20.
RineyJNHollandsJMSmithJR, et al.Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients. Ann Pharmacother. 2010;44:1141-1151.
21.
FanJJohnBTesdalE. Evaluation of heparin dosing based on adjusted body weight in obese patients. Am J Health Syst Pharm. 2016;73(19):1512-1522.
22.
PollackCVSchreiberDGoldhaberSZ, et al.Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: Initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardio. 2011;57(6):700-706.
